Jonathan Eric Rosenberg,Eliezer Mendel Van Allen,Levi Alexander Garraway,Philip Wayne Kantoff,Nikhil Wagle
申请号：
US15126423
公开号：
US20170081724A1
申请日:
2015.03.17
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A method of increasing the efficacy of treatment for a patient suffering from urothelial carcinoma. The method comprises the steps of determining the presence or absence in a biological sample from the patient of somatic ERCC2 mutation followed by performing appropriate treatment. The absence of somatic ERCC2 mutation indicates that the urothelial carcinoma is likely to be unresponsive to cisplatin chemotherapy, and the patient then undergoes surgery to remove the carcinoma without accompanying cisplatin chemotherapy. The presence of somatic ERCC2 mutation indicates that the uroethelial carcinoma is likely to be responsive to cisplatin chemotherapy and the patient then undergoes surgery to remove the carcinoma accompanied by cisplatin chemotherapy.
